Skip to main content
. 2021 Sep 14;22(2):209–221. doi: 10.1016/S1473-3099(21)00485-0

Figure 3.

Figure 3

Normalised SARS-CoV-2 viral loads in nasopharyngeal swabs in the intention-to-treat population at each timepoint and as change from baseline, according to treatment group and COVID-19 severity at random assignment

Data are mean (95% CI). Green lines show the remdesivir group. Blue lines show the control group. LSMD=least-square mean difference.